Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial
Study context
- Population
- Initial treatment of mild to moderate hypertension (SBP/DBP 140–179/90–109 mm Hg)planned sample size
- Participants
- 90 participants
- Planned comparison
- Half-dose quadruple therapy vs standard-dose dual therapy
- Primary endpoint
- BP reduction and adverse effects of the 2 combinations
- Follow-up
- 4 weeks per period
Methodological detailsdouble-blind, 1:1 randomisation, 2-week wash-out, Started July 2022; expected completion August 2023, Each combination for 4 weeks, then switch, with 2-week wash-out
- Double-blind
- 1:1 randomisation
- 2-week wash-out
- Started July 2022; expected completion August 2023
- Each combination for 4 weeks, then switch, with 2-week wash-out
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial. Am Heart J. Published 4 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →